Related Experiment Video
Updated: Aug 5, 2026
Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Selection of a variant lymphoma cell deficient in adenylate cyclase
Abstract:
Isoproterenol, a stimulator of adenylate cyclase, was used to select a stable variant clone of mouse lymphosarcoma cells deficient in the enzyme. The inability of four different stimulators to activate cyclic adenosine monophosphate synthesis in the variant, in contrast to its wild-type parent, implies that in normal cells one type of adenylate cyclase molecular can respond to different activators.
Insights
Researchers identified a mouse lymphosarcoma cell variant lacking adenylate cyclase. This finding suggests a single molecular type of adenylate cyclase can respond to various activators in normal cells.
Area of Science:
- Biochemistry
- Cell Biology
- Molecular Pharmacology
Background:
- Adenylate cyclase is a key enzyme in cellular signaling pathways.
- Cyclic adenosine monophosphate (cAMP) is a crucial second messenger regulated by adenylate cyclase.
- Understanding adenylate cyclase regulation is vital for comprehending cellular responses to external stimuli.
Purpose of the Study:
- To investigate the molecular mechanisms of adenylate cyclase activation.
- To determine if different activators interact with the same adenylate cyclase molecular entity.
- To characterize a variant cell line with altered adenylate cyclase activity.
Main Methods:
- Selection of a stable variant clone of mouse lymphosarcoma cells.
- Utilizing isoproterenol as a specific stimulator of adenylate cyclase.
- Assessing the ability of four different stimulators to activate cyclic adenosine monophosphate synthesis.
Main Results:
- A stable variant clone deficient in adenylate cyclase was successfully isolated.
- The variant clone showed no activation of cAMP synthesis in response to any of the four tested stimulators.
- The wild-type parent cells exhibited normal cAMP synthesis activation.
Conclusions:
- A single type of adenylate cyclase molecule in normal cells can respond to diverse activators.
- This study provides evidence for the molecular basis of adenylate cyclase responsiveness.
- The findings have implications for understanding signal transduction pathways and drug development targeting adenylate cyclase.
